S’ Disclosures

Jan 9, 2025 | aacrjournals.org | S’ Disclosures |East Lansing

Table 3 shows unadjusted and adjusted OR for sociodemographic and health-related factors that were considered possible predictors of LCS uptake. In the adjusted model, participants of ages 65 to 79 years were 75% (OR, 1.75; 95% CI, 1.54–1.99) more likely to undergo LCS than their younger counterparts (i.e., 50–64 years). Female participants were 17% (OR, 0.83; 95% CI, 0.73–0.94) less likely to undergo LCS than their male counterparts.

Jan 6, 2025 | aacrjournals.org | S’ Disclosures

In the era of precision prevention and tailored screening, there is an increasing emphasis on getting the right prevention to the right women at the right time and tailoring screening examination protocols to women based on individual risk. Underpinning this approach is the need for accurate risk assessments that can be generated and delivered in real time in the clinic (1).

Oct 15, 2024 | aacrjournals.org | S’ Disclosures

Metastatic dormancy is a significant clinical problem for the 3.8 million women in the United States with breast cancer (1). Most women will have early-stage diagnosis and receive therapy that is curative on the scale of 5 to 10 years. However, many of these patients will recur with metastatic disease 10 years or more after initial diagnosis (2). The risk factors for recurrence are unclear, but evidence suggests a role for immune system function (3).

Oct 1, 2024 | aacrjournals.org | S’ Disclosures

Immunoprevention, an emerging approach to improve antitumor immune surveillance, is being considered for solid tumors such as pancreatic ductal adenocarcinoma (PDAC). Pancreatic intraepithelial neoplasia (PanIN) is a precursor to PDAC, and mutations in KRAS are common in PanIN. As shown previously, PanIN lesions are present in most adult healthy human pancreas tissue (1, 2).

Sep 16, 2024 | aacrjournals.org | S’ Disclosures

Recent investigations by our lab and others identified wild-type isocitrate dehydrogenase 1 (wtIDH1) as a key therapeutic target against cancer, including pancreatic ductal adenocarcinoma (PDAC; refs. 1–9). The protein is a cytosolic enzyme that is similar in function to the mitochondrial enzymes IDH2 and 3A. It catalyzes the interconversion of isocitrate and α-ketoglutarate (αKG) using NADP(H) as a cofactor (1–3).